About Maxygen
Maxygen is a company based in Redwood City (United States) founded in 1997 by Willem Pim Stemmer. Maxygen offers products and services including EvoGenerative Methods and DNA Services. Maxygen operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Redwood City, United States
- Founders Willem Pim Stemmer
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Maxygen Inc
-
Annual Revenue
$30.01 M (USD)5250as on Dec 31, 2012
-
Net Profit
$20.57 M (USD)-60as on Dec 31, 2012
-
EBITDA
$20.26 M (USD)273as on Dec 31, 2012
-
Latest Funding Round
$850.02 K (USD), Grant
Sep 24, 2008
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Maxygen
Maxygen offers a comprehensive portfolio of products and services, including EvoGenerative Methods and DNA Services.
Scalable library design for directed evolution in protein engineering.
Synthesis, assembly, and cloning technologies for biotechnology workflows.
Funding Insights of Maxygen
Investors in Maxygen
Maxygen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked |
Investor details for Maxygen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Maxygen
Investment portfolio details for Maxygen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Maxygen
Detailed financials for Maxygen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Maxygen Comparisons
Peer comparison for Maxygen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Maxygen
Maxygen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
Detailed competitors of Maxygen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Maxygen
Complete news archive for Maxygen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Maxygen
Maxygen was founded in 1997 and raised its 1st funding round 11 years after it was founded.
Maxygen is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Annual revenue of Maxygen is $30.01M as on Dec 31, 2012.
Maxygen was founded in 1997 and is based in Redwood City, United States. Operations focus on biotechnology, with protein therapeutics provided for chemotherapy-induced neutropenia. A novel G-CSF is featured in clinical programs for this condition. Preclinical efforts include MAXY-4, a CTLA4-Ig developed for rheumatoid arthritis and other autoimmune diseases. Development occurs within the pharmaceutical sector targeting immune-related disorders.
Maxygen's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Maxygen offers EvoGenerative Methods and DNA Services.
Maxygen has 1 investor. Key investors include Military Health.